Advertisement
ALDX Novinky na Forexe
Aldeyra Therapeutics Gets CRL From FDA For NDA Of ADX-2191 To Treat Primary Vitreoretinal Lymphoma
Biotechnology company Aldeyra Therapeutics, Inc. (ALDX) announced Wednesday the receipt of a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for the 505(b)(2) New Drug Application (NDA) of ADX-2191 (methotrexate for injection, USP), an investigational drug candidate, for the treatment of primary vitreoretinal lymphoma (PVRL).
RTTNews
|
Pred 697 dňami
Aldeyra Therapeutics Achieves Goals In Crossover Clinical Trial Of 0.25% Reproxalap Solution
Aldeyra Therapeutics, Inc. (ALDX) announced Tuesday the achievement of the primary endpoints in a sequence-randomized, double-masked, vehicle-controlled crossover clinical trial of 0.25% reproxalap ophthalmic solution, an investigational new drug candidate, for the treatment of dry eye disease.
RTTNews
|
Pred 1041 dňami
